Plasma Aβ42/Aβ40 and p-tau181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive Impairment
Zhenxu Xiao(Fudan University), Qianhua Zhao(Fudan University), Wanqing Wu(Fudan University), Xiaoxi Ma(Fudan University), Ding Ding(Fudan University), Li Zheng(Fudan University), Jianfeng Luo(Chinese Academy of Medical Sciences & Peking Union Medical College), Keliang Chen(Fudan University), Xiaoniu Liang(Fudan University), Jiaying Lu(Fudan University), Saineng Ding(Fudan University), Qiqi Lei(South China Agricultural University)
Cited by 32
Related Papers
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2023|892
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
|Alzheimer s Research & Therapy|2021|200
Environmental occurrence, toxicity concerns, and biodegradation of neonicotinoid insecticides
|Environmental Research|2022|169
Bioremediation potential of laccase for catalysis of glyphosate, isoproturon, lignin, and parathion: Molecular docking, dynamics, and simulation
|Journal of Hazardous Materials|2022|128